LFCR Q4 2023 Earnings — Lifecore Biomedical, Inc. Revenue & Financial Results | Market Cap Arena

LFCRLifecore Biomedical, Inc.

$267M

Q4 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$26M-46.4% YoY

Gross Profit

$8M33.0% margin

Operating Income

-$1M-4.8% margin

Net Income

-$36M-139.4% margin

EPS (Diluted)

$-1.19

QoQ Revenue Growth

-3.8%

Cash Flow

Operating Cash Flow

-$272,000

Free Cash Flow

-$9M

Stock-Based Comp.

$816,000

Balance Sheet

Total Assets

$254M

Total Liabilities

$258M

Stockholders' Equity

-$4M

Cash & Equivalents

$19M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$26M	$48M	-46.4%
Gross Profit	$8M	$11M	-25.7%
Operating Income	-$1M	-$39M	+96.8%
Net Income	-$36M	-$37M	+3.0%